阿哌沙班，阿哌沙班原料药，阿哌沙班工厂

Product name: Apixaban

Cas NO.: 503612-47-3

M.F: C25H25N5O4

M.W.: 459.5

Capacity: 200KG/M

Usage: Cerebro-cardiovascular

General: Apixaban is a potent, orally active, reversible, direct, and highly selective factor Xa active site inhibitor with antithrombotic activity. Apixaban inhibits free and thrombus-bound factor Xa and inhibits prothrombin activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits thrombin-induced platelet aggregation. Through inhibition of factor Xa, apixaban inhibits thrombin generation and inhibits thrombus formation. The preclinical test results in animal models show that apixaban has antithrombotic effect at a dose level that does not affect the hemostatic function, and can prevent arterial and venous thrombosis. 

Product introduce: Apixaban is an anticoagulant used to prevent venous thromboembolism and atrial fibrillation stroke. It is a direct factor Xa inhibitor. Apixaban can be used for antithrombotic therapy in patients with acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) of atrial fibrillation. Clinical trials have confirmed the safety and effectiveness of Apixaban in patients with atrial fibrillation at the recommended dose. A new oral anticoagulant including Apixaban combined with P2Y12 inhibitor is currently recommended by North American guidance for preventing stroke and systemic embolism in patients with ACS or PCI with atrial fibrillation.

Function：Apixaban can prevent thrombin generation and thrombosis, and play an anticoagulant role by inhibiting coagulation factor Xa.

Origin: Apixaban has been listed in Europe since May 2011. The drug was developed by a joint venture between Pfizer and Bristol-Myers Squibb.

Drug efficacy: Apixaban is the third new oral anticoagulant listed after dabigatran and rivaroxaban. It has been approved in Europe to prevent venous thromboembolic events in patients undergoing elective hip or knee replacement surgery. The experimental results of these three oral anticoagulants show that rivaroxaban and apixaban stand out in the RECORD test and the ADVANCE test respectively. Experts say that rivaroxaban seems to have a slightly better effect, but the bleeding situation is more serious than that of apixaban. Experts attribute these differences to the time of administration. In the RECORD trial, rivaroxaban was administered 6-8 hours after operation, while in the ADVANCE trial, apixaban was administered 18 hours after operation. The closer the administration time of these drugs is to the operation, the better the curative effect, but the higher the risk of bleeding.